Metabolomics of pulmonary hypertension:from pathological mechanisms to therapeutic targets
10.16352/j.issn.1001-6325.2024.08.1074
- VernacularTitle:肺动脉高压代谢组学:从病理机制到治疗靶点
- Author:
Yuanrui DENG
1
;
Xiaojian WANG
Author Information
1. 中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院心血管疾病国家重点实验室,北京 100037
- Keywords:
metabolomics;
pulmonary hypertension
- From:
Basic & Clinical Medicine
2024;44(8):1074-1079
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension(PH)is a severe cardiovascular disease characterized primarily by pulmonary vascular remodeling.Patients with PH typically exhibit significant metabolic abnormalities including disruptions in energy metabolism,alterations in lipid and amino acids metabolism.These metabolic disturbances are closely linked to pathophysiological processes such as pulmonary vascular remodeling,endothelial dysfunction and right ventricular hypertrophy.In recent years,there has been rapid progress in the field of metabolomics related to PH.From the early identification of differential metabolic products to the current exploration of potential therapeutic tar-gets,metabolomics has deepened the understanding of the pathogenesis of PH.These researches have accelerated the discovery and screening of potential therapeutic targets,with some findings already translated into clinical prac-tice to support diagnosis,treatment and prognostic evaluation of PH.
